{
  "Variants Include": [
    {
      "Gene": "TDP-43",
      "variants": [
        {
          "HGVS": "NM_032043.2:c.1489C>G",
          "cDNA Change": {
            "transcript": "NM_032043.2",
            "ref": "C",
            "alt": "G",
            "position": "1489"
          },
          "Protein Change": {
            "ref": "R",
            "alt": "H",
            "position": "497"
          },
          "Description in input context": "R497H mutation in TDP-43"
        }
      ]
    },
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_057173.3:c.6056A>G",
          "cDNA Change": {
            "transcript": "NM_057173.3",
            "ref": "A",
            "alt": "G",
            "position": "6056"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "p.G2019S mutation in LRRK2"
        }
      ]
    },
    {
      "Gene": "SOD1",
      "variants": [
        {
          "HGVS": "NM_000346.2:c.439G>A",
          "cDNA Change": {
            "transcript": "NM_000346.2",
            "ref": "G",
            "alt": "A",
            "position": "439"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "147"
          },
          "Description in input context": "frameshift mutation p.A147T in SOD1"
        }
      ]
    }
  ],
  "Described Disease": {
    "Disease Name": "Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease",
    "MONDO Term": "MONDO:0005536 (ALS) and MONDO:0001689 (Parkinson's Disease)"
  },
  "Experiment Method": [
    {
      "Assay Method": "Western Blot",
      "Material Used": "Transgenic mouse brain tissue and wild-type controls",
      "Readout Type": "Quantitative (protein expression levels of TDP-43 and α-synuclein)",
      "Conclusion": "R497H mutation in TDP-43 increases aggregation, while α-synuclein oligomers correlate with neurodegeneration",
      "Molecular Effect": "Enhanced TDP-43 aggregation and α-synuclein toxicity",
      "Controls": "Wild-type mice and sham-operated controls",
      "Statistical Method": "ANOVA with post-hoc Tukey's test",
      "Thresholds": {
        "Normal": "TDP-43 expression ≤ 1.5-fold increase over wild-type",
        "Abnormal": "TDP-43 expression ≥ 2.0-fold increase over wild-type"
      },
      "Approved Assay": "Yes (commonly used in neurodegenerative disease research)"
    },
    {
      "Assay Method": "Immunohistochemistry",
      "Material Used": "Postmortem brain tissue from ALS patients with LRRK2 p.G2019S mutation",
      "Readout Type": "Qualitative (neuronal loss and Lewy body pathology)",
      "Conclusion": "LRRK2 p.G2019S mutation correlates with accelerated Lewy body formation",
      "Molecular Effect": "Increased phosphorylation of LRRK2 and α-synuclein",
      "Controls": "ALS patients without LRRK2 mutations",
      "Statistical Method": "Chi-square test for categorical differences",
      "Thresholds": {
        "Normal": "Lewy body density ≤ 5 per 1000 μm²",
        "Abnormal": "Lewy body density ≥ 10 per 1000 μm²"
      },
      "Approved Assay": "Yes (standard in Parkinson's disease pathology studies)"
    },
    {
      "Assay Method": "Electrophysiology",
      "Material Used": "SOD1 p.A147T transgenic mice and wild-type controls",
      "Readout Type": "Quantitative (neuronal firing rates and action potential duration)",
      "Conclusion": "SOD1 p.A147T mutation causes rapid motor neuron degeneration",
      "Molecular Effect": "Impaired potassium channel function and increased excitotoxicity",
      "Controls": "Wild-type mice and SOD1 WT transgenic mice",
      "Statistical Method": "Repeated measures ANOVA",
      "Thresholds": {
        "Normal": "Firing rate ≥ 5 Hz, action potential duration ≤ 2.5 ms",
        "Abnormal": "Firing rate < 2 Hz, action potential duration > 3.5 ms"
      },
      "Approved Assay": "Yes (gold standard for motor neuron function assessment)"
    }
  ]
}